Liat MBA - Galmed Pharmaceuticals Chief Officer
| GLMD Stock | USD 2.86 0.01 0.35% |
Executive
Liat MBA is Chief Officer of Galmed Pharmaceuticals
| Age | 57 |
| Address | 16 Abba Hillel Road, Ramat Gan, Israel, 5250608 |
| Phone | 972 3 693 8448 |
| Web | https://www.galmedpharma.com |
Galmed Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2931) % which means that it has lost $0.2931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5267) %, meaning that it created substantial loss on money invested by shareholders. Galmed Pharmaceuticals' management efficiency ratios could be used to measure how well Galmed Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.57, whereas Return On Tangible Assets are forecasted to decline to (0.44). At present, Galmed Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 9.93, whereas Other Current Assets are forecasted to decline to about 410.4 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ellen Cavaleri | Lyra Therapeutics | N/A | |
| Richard MD | Lyra Therapeutics | 61 | |
| Ronan JD | Lyra Therapeutics | 51 | |
| JD Esq | Centessa Pharmaceuticals PLC | N/A | |
| Ray Knox | Lyra Therapeutics | N/A | |
| April Dovholuk | Centessa Pharmaceuticals PLC | N/A | |
| David Wambeke | DiaMedica Therapeutics | 40 | |
| Gloria Cosgrove | Lyra Therapeutics | N/A | |
| Ambarish Shah | DiaMedica Therapeutics | N/A | |
| Patrick MD | Centessa Pharmaceuticals PLC | N/A | |
| Julie CCRP | DiaMedica Therapeutics | 50 | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Allison Nance | Lyra Therapeutics | N/A | |
| Robert MD | Lyra Therapeutics | N/A | |
| Corinne Noyes | Lyra Therapeutics | 56 | |
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| John Bishop | Lyra Therapeutics | 62 | |
| Ellie MD | Centessa Pharmaceuticals PLC | N/A | |
| Robert Richard | Lyra Therapeutics | 66 | |
| MS MD | DiaMedica Therapeutics | 51 | |
| Vineeta Belanger | Lyra Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.29 |
Galmed Pharmaceuticals Leadership Team
Elected by the shareholders, the Galmed Pharmaceuticals' board of directors comprises two types of representatives: Galmed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galmed. The board's role is to monitor Galmed Pharmaceuticals' management team and ensure that shareholders' interests are well served. Galmed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galmed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allen Baharaff, Co-Founder, CEO and President and Director | ||
| Shani Ganon, Human Manager | ||
| Tali Gorfine, Medical Consultant | ||
| Yael Hollander, Vice Strategy | ||
| Guy Nehemya, COO Officer | ||
| Niv Alon, Head PMO | ||
| Doron Cohen, Chief Officer | ||
| Yohai CPA, Chief Officer | ||
| Liat MBA, Chief Officer | ||
| Liat Hayardeny, Chief Officer |
Galmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galmed Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (7.86 M) | ||||
| Shares Outstanding | 1.66 M | ||||
| Shares Owned By Insiders | 1.28 % | ||||
| Shares Owned By Institutions | 0.48 % | ||||
| Number Of Shares Shorted | 17.42 K | ||||
| Price To Earning | (6.79) X | ||||
| Price To Book | 0.26 X | ||||
| EBITDA | (6.87 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.